ABSTRACT
Background: COVID-19 has severely influenced all aspects of life since its emergence and one of the strategies to end this pandemic rest on the vaccination to achieve herd immunity. While vaccinations are usually a safe and effective tool, the abbreviated development process of the available COVID -19 vaccines has increased uncertainties about the safety among the general population especially among patients with immune-mediated diseases (IMD) such as RMD. Method(s): This was a cross sectional study looking at the incidence of adverse events within a month following COVID-19 vaccination among the RMD patients attended rheumatology clinic at the Hospital Tuanku Ja'afar Seremban (HTJS) from 1 May 2021 to 31 September 2021. Result(s): 549 patients were recruited with mean age of 51.5 years. Majority (n = 417, 76%) were females. 414 (75.4%) received Pfizer/ BioNTech, 127 (23.1%) received Sinovac, 7 (1.3%) received Oxford/ AstraZeneca and 1 (0.2%) received Moderna. 35 (6.3%) patients had COVID-19 infection with half of them contracted the infection after at last 1 dose of vaccine. The underlying RMD included RA (n = 217, 39.5%), SLE (n = 122, 22.2%), gout (n = 65, 11.8%), osteoarthritis (n = 41, 7.5%) and psoriatic arthritis (n = 30, 5.5%). 288 (52.4%) patients did not report any side effects following the vaccination. Pain at the site of the injection (n = 169, 30.8%) was the most common side effects, followed by muscle pain (n = 91, 16.4%), fever (n = 90, 16.4%), joint pain (n = 55, 10%) and tiredness (n = 43, 7.7%). 30 (5.4%) cases of RMD flares were reported following the vaccination. 25 were arthritis flare, 3 were SLE flare (2 renal and 1 mucocutaneous involvement) and 2 were psoriasis flare. There were no serious adverse events that required hospitalization. Conclusion(s): This study supports the overall safety of COVID-19 vaccines in patients with RMD. This information can help to overcome vaccine hesitancy among this population.